Methods of treating hidradenitis suppurativa

A method of treating hidradenitis suppurativa (HS) in a subject, comprising administering to the subject a therapeutically effective amount of lutikizumab, wherein the therapeutically effective amount of lutikizumab comprises:

• (1) a first dose of lutikizumab comprising about 300 mg to about 600 mg of lutikizumab, wherein the first dose is administered to the subject at Week 0 (Day 1),
• (2) a second dose of lutikizumab comprising about 300 mg of lutikizumab, wherein the second dose is administered to the subject at Week 1 (Day 8), and
• (3) one or more further doses of lutikizumab, each comprising about 300 mg of lutikizumab, wherein the one or more further doses are administered to the subject at:
• (a) Week 2 (Day 15) and every week or every other week thereafter for a period of time;
• or (b) Week 3 (Day 22) and every other week thereafter for a period of time.

A method of treating hidradenitis suppurativa (HS) in a population of subjects, comprising administering to each subject in the population:

• (1) a first dose of lutikizunab comprising about 300 mg to about 600 mg of lutikizumab, wherein the first dose is administered to each subject at Week 0 (Day 1);
• (2) a second dose of lutikizunab comprising about 300 mg of lutikizumab, wherein the second dose is administered to each subject at Week 1 (Day 8);
• and
• (3) one or more further doses of lutikizumab, each comprising about 300 mg of lutikizumab, wherein the one or more further doses are administered to each subject at:
• (a) Week 2 (Day 15) and every week or every other week thereafter for a period of time;
• or (b) Week 3 (Day 22) and every other week thereafter for a period of time,
• wherein the severity and/or duration of hidradenitis suppurativa (HS) or one or more symptoms thereof is reduced or ameliorated in a greater proportion of the population of subjects as compared to a population of subjects administered with a placebo.

A method of treating hidradenitis suppurativa (HS) in a subject, comprising administering to the subject a therapeutically effective amount of lutikizumab, wherein the therapeutically effective amount of lutikizumab comprises:

• (1) a first dose of lutikizumab comprising about 600 mg of lutikizumab, wherein the first dose is administered to the subject at Week 0 (Day 1);
• (2) a second dose of lutikizumab comprising about 300 mg of lutikizumab, wherein the second dose is administered to the subject at Week 1 (Day 8);
• and
• (3) one or more further doses of lutikizumab, each comprising about 300 mg of lutikizumab, wherein the one or more further doses are administered to the subject at Week 2 (Day 15) and every week thereafter for a period of time.